Patents by Inventor Kevan M. Shokat

Kevan M. Shokat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20240109845
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.
    Type: Application
    Filed: March 31, 2023
    Publication date: April 4, 2024
    Inventors: Kevan M. Shokat, Daniel Gentile, Steven Moss
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20240067656
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: October 19, 2023
    Publication date: February 29, 2024
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11891402
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: February 6, 2024
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11718630
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: August 8, 2023
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230242548
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: November 23, 2022
    Publication date: August 3, 2023
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • RAS INHIBITORS AND USES THEREOF
    Publication number: 20230242586
    Abstract: Described herein, inter alia, are Ras inhibitors and uses thereof.
    Type: Application
    Filed: April 23, 2021
    Publication date: August 3, 2023
    Inventors: Kevan M. Shokat, Hiroaki Suga, Ziyang Zhang, Rong Gao
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230135350
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: October 27, 2022
    Publication date: May 4, 2023
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • STABILIZATION OF MHC COMPLEXES
    Publication number: 20230111132
    Abstract: Provided, inter alia, are methods and compositions for treating cancer.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 13, 2023
    Inventors: Kevan M. Shokat, Ziyang Zhang
  • KINASE ANTAGONISTS
    Publication number: 20230111917
    Abstract: The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.
    Type: Application
    Filed: March 31, 2022
    Publication date: April 13, 2023
    Inventors: Zachary A. Knight, Beth Apsel, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11603376
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: March 14, 2023
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • IMMUNOPHILIN BINDING AGENTS AND USES THEREOF
    Publication number: 20230063768
    Abstract: Described herein, inter alia, are immunophilin binding compounds and methods of heating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.
    Type: Application
    Filed: February 6, 2020
    Publication date: March 2, 2023
    Inventors: Kevan M. Shokat, Ziyang Zhang, William A. Weiss, QiWen Fan
  • CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
    Publication number: 20220289866
    Abstract: The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.
    Type: Application
    Filed: July 10, 2020
    Publication date: September 15, 2022
    Applicant: The Regents of the University of California
    Inventors: Charles S. CRAIK, Kevan M. SHOKAT, Ziyang ZHANG, Peter J. ROHWEDER
  • Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
    Patent number: 11427588
    Abstract: Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: August 30, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MITOKININ, INC.
    Inventors: Nicholas T. Hertz, Kevan M. Shokat, Robert DeVita
  • IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF
    Publication number: 20220193242
    Abstract: Disclosed herein, inter alia, are immunophilin binding compounds and methods of using the same.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 23, 2022
    Inventors: Kevan M. Shokat, Ziyang Zhang
  • AURORA KINASE INHIBITORS
    Publication number: 20220054489
    Abstract: Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.
    Type: Application
    Filed: August 30, 2021
    Publication date: February 24, 2022
    Inventors: Justin Gabriel Meyerowitz, William Clay Gustafson, William A. Weiss, Nicholas T. Hertz, Kevan M. Shokat
  • Compositions and methods for treating parasitic diseases
    Patent number: 11208411
    Abstract: Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: December 28, 2021
    Assignees: The Regents of the University of California, Washington University
    Inventors: Florentine Rutaganira, Kevan M. Shokat, Laurence David Sibley, James W. Janetka
  • Aurora kinase inhibitors
    Patent number: 11135222
    Abstract: Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: October 5, 2021
    Assignee: THE REGENTS OF THE UNIVERSIITY OF CALIFORNIA
    Inventors: Justin Gabriel Meyerowitz, William Clay Gustafson, William A. Weiss, Nicholas T. Hertz, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11136297
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: October 5, 2021
    Assignee: The Regents of the University of California
    Inventors: Kevan M. Shokat, Daniel Gentile, Steven Moss
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20210230183
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 29, 2021
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11008334
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: May 18, 2021
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat